Royal Philips, the parent company of Philips Healthcare, said it has acquired CardioProlific, a U.S.-based firm that is developing catheter-based thrombectomy products to treat peripheral vascular disease. Terms of the deal were not disclosed.
CardioProlific's technologies are complementary to Philips' portfolio of image-guided therapy devices and to those of Spectranetics, another recent acquisition, according to Philips.
Philips said that CardioProlific's differentiated thrombectomy technologies, combined with its own image-guided therapy products, will advance innovation in the treatment of peripheral vascular disease.
